Candel Therapeutics, Inc. CADL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.84M+145% | $11.03M+129% | $8.46M+56.2% | $6.99M+40.4% | $4.02M-2.1% | ||
| $6.44M+56.6% | $4.72M+42.1% | $4.75M+42.1% | $4.19M+16.5% | $4.11M+8.3% | ||
| $16.28M+100% | $15.75M+93.5% | $13.21M+50.8% | $11.18M+30.4% | $8.13M+2.9% | ||
| $16.28M+100% | $15.75M+93.5% | $13.21M+50.8% | $11.18M+30.4% | $8.13M+2.9% | ||
| -$16.28M-100% | -$15.75M-93.5% | -$13.21M-50.8% | -$11.18M-30.4% | -$8.13M-2.9% | ||
| $1.56M+411% | $1.42M+263% | $161K-66.9% | $236K-58.4% | $306K-52.6% | ||
| $1.32M+41.5% | $1.1M+280% | $953K+304% | $926K+286% | $934K+192% | ||
| $7.42M-52.1% | —— | $1.94M+203% | $6.38M+147% | $15.51M+4,962% | ||
| $22K-1.1% | $22.25K— | $22.25K— | $22.25K— | $22.25K— | ||
| -$8.86M-220% | -$29.5M-110% | -$11.27M-5.9% | -$4.8M+78.4% | $7.38M+190% | ||
| -$0.14-208% | -$0.55-41.0% | -$0.21+36.4% | -$0.09+87.8% | $0.13+146% | ||
| -$0.14-193% | -$0.55-41.0% | -$0.21+36.4% | -$0.09+87.8% | $0.15+154% | ||
| 62.4M+13.9% | 53M+67.2% | 54.9M+71.5% | 51.5M+72.3% | 54.8M+87.6% | ||
| 62.4M+23.5% | 53M+67.2% | 54.9M+71.5% | 51.5M+72.3% | 50.5M+72.9% | ||
| $1.32M+41.5% | $1.1M+280% | $953K+304% | $926K+286% | $934K+192% | ||
| -$16.28M-100% | -$15.75M-93.5% | -$13.21M-50.8% | -$11.18M-30.4% | -$8.13M-2.9% | ||
| -$16.14M-105% | -$15.59M-97.4% | -$13.01M-52.0% | -$10.98M-31.1% | -$7.89M-3.1% | ||
| -$16.14M-105% | -$15.59M-97.4% | -$13.01M-52.0% | -$10.98M-31.1% | -$7.89M-3.1% | ||
| -$16.28M-100% | -$15.75M-93.5% | -$13.21M-50.8% | -$11.18M-30.4% | -$8.13M-2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Candel Therapeutics, Inc.'s revenue?
- Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
